Harvard Bioscience, Inc. provided earnings guidance for the full year 2024. For the full year 2024, the company expects revenues to be approximately flat versus 2023. The company expects second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 USD | -2.62% | -5.10% | -37.38% |
07/05 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
07/05 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.38% | 15Cr | |
+12.15% | 23TCr | |
+14.90% | 20TCr | |
+18.22% | 14TCr | |
+29.15% | 11TCr | |
+0.53% | 6.41TCr | |
+16.92% | 5.37TCr | |
+6.33% | 5.17TCr | |
+10.93% | 4.52TCr | |
+5.87% | 3.74TCr |
- Stock Market
- Equities
- HBIO Stock
- News Harvard Bioscience, Inc.
- Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024